Year: 2021

BOCA RATON, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that Jushi’s management will participate in two upcoming events in November 2021:Viridian Capital Cannabis Expert Series on Wednesday, November 10, 2021. Olivier Blechner, EVP of Business Development, to participate in a fireside chat at 10:00 a.m. ET.  Please click here to register for the fireside chat.Cowen’s 4th Annual Cannabis Conference is being held on November 29 – December 1, 2021. Jim Cacioppo, Chief Executive Officer, Chairman and Founder is scheduled to participate in a panel discussion entitled, “U.S. MSOs: The North-East” on Monday, November 29, 2021, at 10:30 a.m. ET and will be participating in virtual one-on-one investor...

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022 Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) On track to initiate first-in-human studies of NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) by year-end Announces nomination of NTLA-3001, its first gene insertion development candidate, for alpha-1 antitrypsin deficiency (AATD); concurrently, Regeneron and Intellia have selected a Factor 9 gene insertion development candidate to advance for hemophilia B (Hem B) Presented new data on its proprietary and differentiated allogeneic cell engineering platform and ex vivo LNP-based delivery of CRISPR/Cas9 to T cells...

VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; ARREF: OTC) (“Amerigo” or the “Company”) regretfully advises the passing of director David Thomas. Mr. Thomas joined the Amerigo board of directors in June 2021. He had more than 40 years of experience in the mining industry, working with Kennecott Copper Corporation, Bougainville Copper Limited, and Austpac Resources in Australia. He also was a Vice President and Technical Director for Mellon Bank and worked at Southern Peru Copper Corporation, where he served as Mine Manager, Area Manager, Chief Engineer and Vice President of Operations. He was Vice President-Technical Services at Freeport Indonesia, and worked as Managing Director of VALCO, an aluminum company in Ghana. David also worked on the team developing the Toromocho Copper...

Albert Weber to join OpGen as OpGen’s CFO effective January 1, 2022 from U.S.-German molecular diagnostics company Epigenomics Announces inducement grant of 210,000 stock options under NASDAQ Listing Rule 5635(c)(4)ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the appointment of Albert Weber as OpGen’s new Chief Financial Officer and Managing Director of OpGen’s subsidiary Curetis GmbH effective January 1, 2022. Mr. Weber is a corporate finance executive who brings more than 30 years of professional experience in accounting, controlling and corporate finance roles. During the last 21 years, he served in several roles for Epigenomics...

MONTREAL, Nov. 04, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2021 financial results on Thursday, November 11, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, November 11, 2021 Time: 8:30 a.m. ET Telephone: Toll Free: 866-269-4264 or International 1-647-792-1240 Webcast: www.gud-knight.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada,...

Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of pancreatic cancer DAY101 received Rare Pediatric Disease Designation for the treatment of pediatric low-grade glioma Ficlatuzumab received Fast Track Designation for the treatment of relapsed or recurrent head and neck squamous cell carcinoma Earned $0.5 million milestone payment from Compugen after their partner, AstraZeneca, dosed the first patient in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody derived from COM902 Welcomed Heather L. Franklin to the Board of Directors, Joyce Chan as Vice President, Scientific Analysis, and Christopher Baldwin as Vice President, Legal Board of Directors declared quarterly dividend payments...

 On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021         First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy          On-track to initiate several proof-of-concept Phase 2a clinical trials with AB-729 as a cornerstone agent in combination with other approved or investigational compounds         Commenced IND enabling studies for Arbutus’ oral PD-L1 program Cash runway guidance extended into the second quarter of 2023 Conference call and webcast scheduled today at 8:45 AM ET WARMINSTER, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action...

First Results Expected in Early DecemberFigure 1Summary drilling results on the Tarabala Trend and the location of the completed diamond drill holes.Figure 2Property map showing the location of the Tarabala prospect.TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) announces that it has completed the first diamond drilling program at the Tarabala prospect on its Sikasso Property in Southern Mali (Figure 2). HighlightsCompleted four diamond drill holes for a total of 520 m Core is being logged for geological information and sampled for gold Results for all drill holes are expected in 4-5 weeksCompass CEO, Larry Phillips, commented, “We have completed our planned diamond drilling at our Tarabala prospect. This drilling has focused on characterizing...

– Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment – – SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tumors: overall response rate of 36% and 86% disease control rate with responses in five different solid tumors – – Initiated Phase 2 SURPASS-2 trial investigating next-generation ADP-A2M4CD8 in patients with esophageal and EGJ cancers – – Will initiate Phase 2 SURPASS-3 trial to investigate ADP-A2M4CD8 in ovarian cancer in 2022 – – Ceased enrollment in the SPEARHEAD-2 trial, and will evaluate the use of checkpoint inhibitors in combination with ADP-A2M4CD8 – – Data presented at ILCA from the ADP-A2AFP Phase 1 trial; screening...

ST. CLOUD, Minn., Nov. 04, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in mass mobility solutions, today announced that the Capital Metro Transportation Authority (“CapMetro”) has awarded NFI subsidiary New Flyer of America Inc. (“New Flyer”) a contract for 26 battery-electric Xcelsior CHARGE NG™ forty-foot heavy-duty transit buses and four battery-electric Xcelsior CHARGE NG™ sixty-foot heavy-duty transit buses (34 equivalent units or “EUs”). The five-year contract includes options to purchase up to 126 forty-foot and up to 15 sixty-foot battery-electric buses, and up to 427 chargers (197 depot plug-in chargers, 197 depot overhead chargers, and 33 on route chargers). This procurement is one of the largest battery-electric...